FDA Warning Letters: Don’t Make the Same Mistakes! Neysa Rhoads, RN, CCRC Preventive Medicine May 3, 2015.

Slides:



Advertisements
Similar presentations
Investigator Responsibilities in Clinical Research
Advertisements

1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Tips to a Successful Monitoring Visit
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
 Patricia Kerby, MPA  Office of Research Compliance  April 8, 2010.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
1 © Huron Consulting Group Inc. All rights reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,
Capturing and Reporting Adverse Events in Clinical Research
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
Management Fraud and Audit Risk
Jennifer McCormick MA, CRC Karla Lichter RN CCRC.
Overview of Good Clinical Practices (GCPs)
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
“So You Think You Know GCP …” Session S794 Jill Matzat, RN, BSN, CCRA, CCRT President, Medical Research Management & CRA Solutions, Inc. Paul Below, CCRA,
HRPP Training – Session Two Human Research Protection Program Manager
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Ethics and Regulatory Approvals Alison Robertson CMDHB Research Officer.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Device Clinical Trials and More… Michael E. Marcarelli, PharmD Director, Division of Bioresearch Monitoring Office of Compliance Center for Devices and.
Planning and Surviving An Audit/Monitoring visit Carmen B. Jacobs, BS, RN,OCN, CCRP U.T. MD Anderson Cancer Center Houston, Texas U.S.A.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
Expedited Procedures Bob Craig June Expedited problems Usually individual investigators (rather than trained coordinators) Individuals not “ active.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
Ensuring Human Subject Protection A Guide for Those who Obtain Research Informed Consent Documents 10/15/20151.
Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
Informed Consent Process: Key Considerations. Introduction  Informed consent is a requirement of ethical clinical research  Section 4.8 of the International.
1 Denise K. Thwing, MAS, RN, CCRA March 31, 2010 Version: Final 31-Mar-2010.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
Noncompliance and Correction (OSEP Memo 09-02) June 2012.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Informed Consent Presented by Marian Serge, RN. Goals Informed consent process and form Title 38 CFR , Common Rule required elements and additional.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Data Management: Source Documents, Case Report Forms and Electronic Data Thomas Salerno, RN BSN MA Senior Team Lead Cardiology Research Jefferson Clinical.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Supervisory Responsibilities of Clinical Investigators
Good Documentation Practices
Good Clinical Practice (GCP) and Monitoring Practices
Instructions for New IRB Continuing Review (Progress) Report
The Role and Responsibilities of the Clinical Research Coordinator
Responsibilities of Sponsor, Investigator and Monitor
IRB reporting updates.
Bozeman Health Clinical Research
Management Fraud and Audit Risk
Elements of an Organized Regulatory Binder
Basics of Building and Understanding Data Collection Forms
Basic Informed Consent Training: Part II
Adapted from On Being a Scientist, 3rd Ed.
TRTO (Translational Research Trials Office)
Research, Experimentation, & Clinical Trials
Event Reporting in Human Subjects Research
Understanding the Process of Documenting Informed Consent
Quality Assurance in Clinical Trials
Katherine Hawthorne, BS, rn, CCRP Program Manager
Good clinical practice
Presentation transcript:

FDA Warning Letters: Don’t Make the Same Mistakes! Neysa Rhoads, RN, CCRC Preventive Medicine May 3, 2015

“Experience is the name everyone gives to their mistakes” --Oscar Wilde

What are Good Clinical Practices? Guidelines for the Investigator Guidelines for the Trial Sponsor Guidelines for the Clinical Trial Protocol Guidelines for the Investigator’s Brochure

Fraud In the broadest sense, a fraud is a deception made for personal gain. The specific legal definition varies by legal jurisdiction. Fraud is a crime, and is also a civil law violation. Many hoaxes are fraudulent, although those not made for personal gain are not technically frauds. Defrauding people of money is presumably the most common type of fraud, but there have also been many fraudulent "discoveries" in art, archaeology, and science. From

Objectives Identify different types of misconduct and falsification in research Discuss causes and consequences of misconduct Learn from other’s mistakes

Synonyms for Fraud & Misconduct Wrong Doing Deception FelonyMalpractice Unethical BehaviorMischief CheatingFelony UnprofessionalSwindling DeceitCrime

Misconduct Three categories of misconduct: –Illusion of Knowledge –Surprisingly Sloppy –Malicious Malfeasance Detecting, Correcting and Preventing FDA Sanctions Resources Woollen, S.W., n.d.

The Illusion of Knowledge Lack of understanding Misconduct of the uninformed kind Examples: Backdating the subject’s signature on a consent form because the subject forgot to date the form, creating source documents from CRF’s, discarding source document after accurate transcription and reporting transcribed data as original.

Surprisingly Sloppy Lazy Inaction, inattention to detail, inadequate staff, lack of supervision Examples: ICF inadvertently not obtained from subjects, blood pressures rounded to the nearest 10mmHg, data estimated rather than actually measured, protocol ignored or shortcuts taken

Malicious Malfeasance Deliberate action to deceive or mislead F _ _ _ _ Examples: creating, altering, recording, or omitting data Data does not represent what actually occurred

Falsification of Data FDA focus: Falsification of Data –Deliberate or repeated noncompliance can be considered misconduct and is secondary focus of FDA

Recognizing Research Misconduct Research misconduct means falsification of data in proposing, designing, performing, recording, supervising or reviewing research or in reporting research results

Consequences Places subjects at possible safety risk Jeopardizes the reliability of the data

What Causes Fraud Study staff that does not have the necessary resources and support to accomplish their tasks Study staff have unreasonable demands placed upon them Grand enrollment incentives Just tell the truth

“Research for Hire: Second of Two Articles. A Doctor’s Drug Studies Turned Into Fraud ” New York Times, May 1999 Dr. Robert Fiddes Reports of Fraud by his staff went unnoticed June 1996, auditors took notice Plead guilty to fraud

“The Emperor Has No Clothes!”

Do’s and Don’ts Do –Fill in all blanks –Enter date and times –Make sure information is accurate and matches throughout the chart –Complete documentation the day of the visit –Write a progress note! –Do the right thing!

Do’s and Don’ts –Don’t Cut corners –Don’t Backdate –Don’t use liquid paper or pencil –Don’t re-create –Don’t perform study related procedures before the ICF is signed

FDA Sanctions Warning Letters Formal Disqualification Clinical Hold Voluntary Agreements Debarment Prosecution

Expectations of an Audit Auditors work on the assumption the records are bogus and the study is a fraud They are taught to carefully review and evaluate the Labs, ECGs & X-Rays Question missing information Look out for denial and shifting of blame Verify then trust

FDA Misconduct

You failed to obtain informed consent of each human subject in accordance with 21 CRF 50 [21 CRF ] Lab samples drawn prior to signing and dating the ICF IRB approved ICF required actual time in which legally effective IC was obtained. No documentation of the actual time. Unable to verify subjects signed & dated prior to protocol specific procedures being conducted on them

You failed to obtain informed consent of each human subject in accordance with 21 CRF 50 [21 CRF ] ICF not approved by IRB ICF not signed prior to implanting investigational device

You failed to obtain informed consent of each human subject in accordance with 21 CRF 50 [21 CRF ] No written documentation that IC was obtained IRB approved a 3 page document. Found subjects who were consented with a 1 page ICF and unapproved ICF’s IRB approved ICF signed after study device was utilized

You failed to obtain informed consent of each human subject in accordance with 21 CRF 50 [21 CRF ] Subject signed consent form for incorrect study Consent not signed until 11 days after study related procedure. Handwritten note states, “I was informed about study and risk-did not sign consent ” No documentation that subject was given copy of the signed informed consent

You failed to obtain informed consent of each human subject in accordance with 21 CRF 50 [21 CRF ] Prior to any study related procedures being performed, subject was given a copy of the ICF to read. Subject was given the opportunity to have her questions answered and wishes to participate in the TREAT trial. Subject willingly signed consent with witness present and copy of signed consent given to subject for her records. Neysa Rhoads, RN

Characteristics of Quality Data Accuracy Immediacy Legibility Durability Integrity Consistency Honesty

Warning Letter Most Recent Warning Letters are on the FDA website Read Them, See What Others Did Wrong Learn from the Mistakes of Others

Summary Knowledge is Power If it Looks Like a Skunk, Acts like a Skunk and Smells Like a Skunk…… IT’S A SKUNK!!!!

“The only real mistake is the one from which we learn nothing” --John Powell

References Wollen, S.W. (2003). Retrieved on 6/13/08 from ppt ppt Wollen, S.W. & Hage, A.E. (2001). Retrieved on 6/13/08 from 1/misconduct.ppt 1/misconduct.ppt Eichenwald, K. & Kolata G. (1999). A doctor’s drug trials turn to fraud. Retrieved from